yes gekkowolf, Medical device company CEOs and marketing directors all over the world are pooping themselves at the thought of OSL riding into town with their 40 patient safety study! You do know SRX SIRT is approved for and plays in completely different cancer types to OSL? Does OSL even have any current data in liver cancers?
you’ve missed the point about the celgene study. We could debate this further but no point. But no sorry buddy, the panco overall survival won’t change much, if at all now from 16m.
@merlin- if you’re right that the trial needs to officially complete before a CE can be considered then if true and BSI told them that, that info should have been communicated to market by now by OSL.
@abdi- yes you’re correct, putting those two studies side by side a fair conclusion is despite higher estimates for survival and PFS for celgene trial, probably no difference and so next reasonable conclusion is that device adds nothing to true state of art chemo ....but needs confirmation by proper RCT. The resection margin stuff Gekkowolf talks about weren’t standardised endpoints in either trial from what I can see so difficult to compare how they were done and reported, quality etc . I’ll in that case reserve head scratching to how almost one year since insufficient benefit rejection they’ve still kept this submission going!
OSL Price at posting:
12.0¢ Sentiment: None Disclosure: Not Held
(20min delay)